株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

中堅医薬品企業によるライセンシング・M&A動向

Mid Pharma Licensing and M&A Trends, 2011-16

発行 Datamonitor Healthcare 商品コード 498955
出版日 ページ情報 英文 68 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1USD=113.38円で換算しております。
Back to Top
中堅医薬品企業によるライセンシング・M&A動向 Mid Pharma Licensing and M&A Trends, 2011-16
出版日: 2017年03月01日 ページ情報: 英文 68 Pages
概要

当レポートでは、中堅医薬品企業によるライセンシングおよびM&Aの動向を調査し、中堅医薬品企業グループの定義・構成、中堅医薬品企業の主な動向、提携・M&Aの件数および・取引額の動向、治療区分・臨床ステージ別の詳細分析、アウトライセンシングおよびオプション取引の動向、主要企業のケーススタディなどをまとめています。

エグゼクティブサマリー

中堅医薬品企業グループ:概要

  • オーナー・構造
  • 地域分布
  • 中堅医薬品企業:優れたR&D実績を拡大
  • 中堅医薬品企業:成長のための事業開発の依存
  • 市場規模・展望
  • 文献

提携・M&Aの件数および・取引額の動向

  • 提携の件数および・取引額の動向
  • M&Aの件数および・取引額の動向
  • 文献

治療領域の内訳・動向

  • 提携
  • M&A
  • 文献

臨床ステージ別の内訳・動向

  • 提携
  • M&A

中堅医薬品企業によるアウトライセンシングの動向

  • 中堅医薬品企業によるアウトライセンシング額の大幅な上昇
  • リスクと費用を半減するアウトライセンシング
  • スピンオフ:幅広い取引を提供
  • 文献

中堅医薬品企業によるオプション取引の動向

  • バイアウトオプション
  • ますます高額化するオプション取引

中堅医薬品企業のケーススタディ

  • Celgene
  • Allergan
  • Merck KGaA・UCB

付録

図表

目次
Product Code: DMKC0169636

Between Q1 2011 and Q3 2016, the nine-company Mid Pharma cohort was responsible for around $200bn in up-front mergers and acquisitions (M&A) value and $10bn in up-front licensing value, driving deal volume and deal value in the biopharmaceutical sector. The total number of alliances peaked in 2014, whereas the up-front value attached to these alliances peaked in

2015. M&A volume has increased every year since 2011, and up-front M&A value peaked in 2015.

The Mid Pharma group signed more than 300 alliance deals, from discovery through to marketed assets, and inked 50 acquisitions during the nearly six-year timeframe. For alliances, the top deal-makers by volume were Merck KGaA and Celgene; in terms of value, Celgene was by far the biggest spender on up-front alliance payments. For M&A, the top buyers were Allergan and Shire (by volume and by value).

Among therapeutic categories, oncology held the top spot in both alliance volume and alliance value. For M&A, there were more acquisitions driven by immunology and inflammation assets than any other therapeutic category. Acquisitions during the period broke multiple records, including the largest-ever biotech acquisition premium and the most money paid for a clinical-stage biotech. However, M&A value was driven by a small handful of large deals in which the target companies' product portfolios and pipelines were diversified across several therapeutic areas.

The majority of alliances focused on technologies and product candidates in early-stage development (discovery or preclinical stage), whereas those companies most likely to be acquired by Mid Pharma members had lead assets on the market or in Phase II development.

The sources for the deal data used in this report are Informa's Medtrack and Strategic Transactions.

TABLE OF CONTENTS

EXECUTIVE SUMMARY

MID PHARMA PEER SET OVERVIEW

  • Ownership and structure
  • Geography
  • Mid Pharma boasts a strong R&D track record
  • Mid Pharma companies still rely on business development for growth
  • Size and scope
  • Bibliography

TRENDS IN ALLIANCE AND M&A VOLUME AND VALUE

  • Alliance volume and value trends
  • M&A volume and value trends
  • Bibliography

THERAPEUTIC AREA BREAKDOWN TRENDS

  • Alliance therapeutic area trends
  • M&A therapeutic area trends
  • Bibliography

CLINICAL STAGE BREAKDOWN TRENDS

  • Alliance clinical stage trends
  • M&A clinical stage trends

MID PHARMA OUT-LICENSING TRENDS

  • Mid Pharma out-licensing value is highly concentrated
  • Out-licensing to halve risk and expense
  • Spin-offs offer a broad range of deals
  • Bibliography

MID PHARMA OPTION-BASED DEAL TRENDS

  • Buyout options exercised
  • Options are getting more expensive

MID PHARMA COMPANY CASE STUDIES

  • Celgene is Mid Pharma's biotech alliance leader
  • Allergan's interest in biotech M&A blooms late
  • Merck KGaA and UCB ally most often with academic institutions

APPENDIX

  • About the author
  • Scope
  • Inclusions and exclusions
  • Categorization and classification

LIST OF FIGURES

  • Figure 1: Mid Pharma alliance volume by deal type, Q1 2011-Q3 2016
  • Figure 2: Mid Pharma alliance volume by company, Q1 2011-Q3 2016
  • Figure 3: Up-front value of Mid Pharma in-licensing deals by company, Q1 2011-Q3 2016
  • Figure 4: Total Mid Pharma alliance up-front value by deal type, Q1 2011-Q3 2016
  • Figure 5: Mid Pharma in-licensing average payments, Q1 2011-Q3 2016
  • Figure 6: Mid Pharma up-front payments as a percentage of total deal value, Q1 2011-Q3 2016
  • Figure 7: Mid Pharma alliance partners by partner type: in- and out-licensing deals, Q1 2011-Q3 2016 Figure 8: M&A volume on the rise in Mid Pharma, Q1 2011-Q3 2016
  • Figure 9: Mid Pharma M&A volume by company, Q1 2011-Q3 2016
  • Figure 10: Mid Pharma up-front M&A value by company, Q1 2011-Q3 2016
  • Figure 11: Mid Pharma total up-front M&A value, Q1 2011-Q3 2016
  • Figure 12: Mid Pharma M&A targets by company type, Q1 2011-Q3 2016
  • Figure 13: Mid Pharma acquisitions, by company and target ownerships, Q1 2011-Q3 2016
  • Figure 14: Average deal premium for Mid Pharma public M&A targets, Q1 2011-Q3 2016
  • Figure 15: Mid Pharma M&A up-front payments as percentage of total potential value, Q1 2011-Q3 2016 Figure 16: Private companies get less up-front in earn-out deals, Q1 2011-Q3 2016
  • Figure 17: Mid Pharma alliance volume, by therapeutic area and deal type, Q1 2011-Q3 2016
  • Figure 18: Mid Pharma up-front alliance value by therapeutic area, Q1 2011-Q3 2016
  • Figure 19: Mid Pharma alliance volume, by company and therapeutic area, Q1 2011-Q3 2016
  • Figure 20: Mid Pharma M&A volume by therapeutic area, Q1 2011-Q3 2016
  • Figure 21: Mid Pharma share of M&A value by therapeutic area, Q1 2011-Q3 2016
  • Figure 22: Mid Pharma M&A deal volume, by company and therapeutic area, Q1 2011-Q3 2016
  • Figure 23: Mid Pharma alliance volume by clinical stage, Q1 2011-Q3 2016
  • Figure 24: Mid Pharma up-front value of in-licensing deals by clinical stage, Q1 2011-Q3 2016
  • Figure 25: Mid Pharma M&A volume by clinical stage of target asset, Q1 2011-Q3 2016
  • Figure 26: Mid Pharma M&A up-front value by clinical stage of target asset, Q1 2011-Q3 2016
  • Figure 27: Mid Pharma up-front payment as a percentage of total potential M&A value, Q1 2011-Q3 2016 Figure 28: Mid Pharma out-licensing value and volume by company, Q1 2011-Q3 2016
  • Figure 29: Mid Pharma out-licensing value and volume by phase, Q1 2011-Q3 2016
  • Figure 30: Mid Pharma out-licensing volume and value by therapeutic area, Q1 2011-Q3 2016
  • Figure 31: Mid Pharma partners underscore spin-off strategies, Q1 2011-Q3 2016
  • Figure 32: Mid Pharma option deals volume and value by company, Q1 2011-Q3 2016
  • Figure 33: Mid Pharma option deals volume and value, Q1 2011-Q3 2016
  • Figure 34: Mid Pharma option deals by clinical stage, Q1 2011-Q3 2016
  • Figure 35: Celgene's in-licensing deals sought out early-stage assets, Q1 2011-Q3 2016
  • Figure 36: Oncology and immunology spaces are Celgene's "sweet spots", Q1 2011-Q3 2016
  • Figure 37: Allergan is becoming a force in biotech M&A, Q1 2011-Q3 2016
  • Figure 38: Mid Pharma goes back to school with academic/research alliances, Q1 2011-Q3 2016

LIST OF TABLES

  • Table 1: Mid Pharma peer set overview
  • Table 2: Top 10 Mid Pharma alliances by up-front value, Q1 2011-Q3 2016
  • Table 3: Top 10 Mid Pharma acquisitions by up-front value, Q1 2011-Q3 2016
  • Table 4: Mid Pharma alliance volume, by company and therapeutic area, Q1 2011-Q3 2016 Table 5: Mid Pharma M&A deal volume, by company and therapeutic area, Q1 2011-Q3 2016
Back to Top